NEW DELHI: Pfizer, the world’s leading pharmaceutical company, has said that it will have differential prices on its Covid-19 vaccine for different countries, as the company aims to make the vaccine available worldwide.
The company’s Indian arm has applied for emergency use authorization (USA) for the Pfizer / BioNTech vaccine against Covid-19 in the country from the Indian drug regulator.
Following UK approval for the vaccine, Pfizer and BioNTech anticipate new regulatory decisions around the world in the coming days and are set to deliver vaccine doses following potential regulatory clearances or approvals, Pfizer had previously said.
“The bottom line in pricing was that we made sure to make it available to everyone quickly,” said Pfizer Inc. President and CEO Albert Bourla at a virtual press conference hosted by the International Federation of Product Manufacturers and Associations. Pharmacists (IFPMA) on Tuesday. .
“We have a level price. It is a price for the developed world based on its GDP, another price, lower for middle-income countries and in low-income countries, such as countries in Africa, etc. We are giving it in a non-profit, “he added.
Even in developed countries, the price is what they can afford. In the United States, the price is $ 19.50, the price of an average meal, Bourla said.
The company is in talks with several governments for the vaccine, he added.
Bourla also said that the company is also working on a new formulation that will be able to avoid the -70 degree requirement and can be stored in simple refrigeration.
The company’s Indian arm has applied for emergency use authorization (USA) for the Pfizer / BioNTech vaccine against Covid-19 in the country from the Indian drug regulator.
Following UK approval for the vaccine, Pfizer and BioNTech anticipate new regulatory decisions around the world in the coming days and are set to deliver vaccine doses following potential regulatory clearances or approvals, Pfizer had previously said.
“The bottom line in pricing was that we made sure to make it available to everyone quickly,” said Pfizer Inc. President and CEO Albert Bourla at a virtual press conference hosted by the International Federation of Product Manufacturers and Associations. Pharmacists (IFPMA) on Tuesday. .
“We have a level price. It is a price for the developed world based on its GDP, another price, lower for middle-income countries and in low-income countries, such as countries in Africa, etc. We are giving it in a non-profit, “he added.
Even in developed countries, the price is what they can afford. In the United States, the price is $ 19.50, the price of an average meal, Bourla said.
The company is in talks with several governments for the vaccine, he added.
Bourla also said that the company is also working on a new formulation that will be able to avoid the -70 degree requirement and can be stored in simple refrigeration.
.
